Real-World Experiences With Faricimab

EP: 1.Impact of First-Line Therapy on Long-Term Outcomes in nAMD and DME

EP: 2.Choosing First-Line Therapy in nAMD or DME

EP: 3.When to Switch to More Efficacious Agents

Now Viewing

EP: 4.Real-World Experiences With Faricimab

EP: 5.Real-World Experiences With Aflibercept 8mg

EP: 6.Efficacy and Durability: New Therapies vs Aflibercept 2mg

EP: 7.Perspectives on Retinal Fluid Management

EP: 8.Perspectives on Loading Dose Recommendations for New Therapies

EP: 9.Safety Considerations for New Therapies

EP: 10.The Impact of Biosimilars in Retinal Diseases

EP: 11.The Status of Gene Therapy Development for Retinal Diseases

EP: 12.Considering Safety of Gene Therapy for Retinal Diseases

EP: 13.Role of Tyrosine Kinase Inhibitors and Gene Therapy in Retinal Diseases

EP: 14.Perspectives on the Future of Retinal Disease Management

Summary

The discussion shifts to the real-world experience with faricimab, focusing on its durability compared to the results reported in clinical trials. David Brown, MD expresses that, while the drug has maintained its safety profile in the real world, its duration of effect has been a point of disappointment. Seenu Hariprasad, MD concurs with Brown's assessment, highlighting that real-world durability often falls short of the optimistic projections seen in clinical trials. In this case, the trial focused on treatment-naïve patients who did experience extended treatment intervals; in clinic, however, these durability outcomes did not transfer to patients who are not treatment-naive. Both panelists emphasize the need to manage patient expectations and caution against overestimating the drug's efficacy in routine clinical settings compared to the controlled environment of clinical trials.

This summary was AI-generated and edited for clarity.